Drug Profile
Research programme: ligand activated therapeutics - Zevra Therapeutics
Alternative Names: KP 214; KP 515; KP 606; KP 612; KP 746; KP303; KP606/IR; KP7xxLatest Information Update: 26 Feb 2023
Price :
$50
*
At a glance
- Originator KemPharm
- Developer Zevra Therapeutics
- Class Dibenzothiazepines; Morphine derivatives; Opioid peptides; Phenylacetates; Piperazines; Piperidines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Opioid receptor agonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute pain; Cardiovascular disorders; CNS disorders; Pain
Most Recent Events
- 22 Feb 2023 KemPharm is now called Zevra Therapeutics
- 28 Apr 2018 No recent reports of development identified for research development in CNS-disorders in USA (PO)
- 23 Jan 2018 KemPharm has patent protection for KP 606 entitled "Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof" in USA